biostudies-literatureCisneros JMFP7 Health383https://www.ebi.ac.uk/biostudies/studies/S-EPMC6883535biostudies-literatureUnknown23(1)<h4>Background</h4>Colistin is recommended in the empirical treatment of ventilator-associated pneumonia (VAP) with a high prevalence of carbapenem-resistant gram-negative bacilli (CR-GNB). However, the efficacy and safety of colistin are not well defined.<h4>Methods</h4>A multicenter prospective randomized trial conducted in 32 European centers compared the efficacy and safety of colistin (4.5 million unit loading dose followed by a maintenance dose of 3 million units every 8 h) versus meropenem (2 g every 8 h), both in combination with levofloxacin (500 mg every 12 h) for 7-14 days in patients with late VAP. Between May 2012 and October 2015, 232 patients were randomly assigned to the 2 treatment groups. The primary endpoint was mortality at 28 days after randomization in the microbiologCritical care (London, England)Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial.PMC6883535278232Gonzalez VSierra RLepe JAPolanco MJPozo JCMalachias SSeller GLopez MDAntonelli MNakos GEstella ABello GGarnacho-Montero Jde la Torre MVMagic Bullet Working Group WP1Ferrer RCisneros JMLeal RKoutsoukou APneumatikos IJimenez-Jorge SGutierrez-Pizarraya AZakinthinos SKomnos AAlvarez-Rocha LEspinosa MCDe Roberts EDiaz-Miguel RORamirez PDi Gravio VAllegue JMHerrera-Gutierrez MEZaragoza RZakynthinos EMatthaiou DKBitsan MDominguez PJDe Pascale GPuppo ARosso-Fernandez CMVillarreal EZafeiridis TFernandez-Hinojosa EDimopoulos GRoca-Oporto CGonzalez AVidal PfalseColistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial.<h4>Background</h4>Colistin is recommended in the empirical treatment of ventilator-associated pneumonia (VAP) with a high prevalence of carbapenem-resistant gram-negative bacilli (CR-GNB). However, the efficacy and safety of colistin are not well defined.<h4>Methods</h4>A multicenter prospective randomized trial conducted in 32 European centers compared the efficacy and safety of colistin (4.5 million unit loading dose followed by a maintenance dose of 3 million units every 8 h) versus meropenem (2 g every 8 h), both in combination with levofloxacin (500 mg every 12 h) for 7-14 days in patients with late VAP. Between May 2012 and October 2015, 232 patients were randomly assigned to the 2 treatment groups. The primary endpoint was mortality at 28 days after randomization in the microbiolog2019-01-01T00:00:00Z2019 Nov2026-05-04T11:32:32.693Z2020-05-21T20:49:56ZS-EPMC68835353177971110.1186/s13054-019-2627-y